Two knock-in mouse models, ZC4H2L66H/y and ZC4H2R213W/y, show similar cognitive deficits—novel-object recognition impairment, social-memory loss, and spatial learning defects—despite opposite synaptic readouts: L66H reduces GABAergic transmission and inhibitory LTP, while R213W increases AMPAR-mediated excitation and impairs excitatory LTP.

The study argues for disease stratification in neurodevelopmental disorders that accounts for molecular pathology and mutation-specific mechanisms, highlighting that phenotypic similarity can hide opposing synaptic etiologies.

Electrophysiological data from hippocampal slices indicate loss-of-function mutations primarily impair inhibitory transmission, whereas gain-of-function mutations enhance excitatory transmission, aligning with their respective synaptic pathologies.

TurboID proximity labeling shows the divergent mechanisms stem from two distinct E3 ubiquitin ligase pathways: L66H promotes GABAA receptor destabilization via MKRN2, while R213W disrupts RNF220 stability, reducing AMPA receptor ubiquitination and boosting excitatory drive.

Source: Ma, P., et al. (2026). Opposing excitatory and inhibitory synaptic pathologies drive ZC4H2-associated intellectual disability. Neuron. DOI: 10.1016/j.neuron.2026.10.008.

Genetic rescue experiments confirm pathway specificity: knocking out MKRN2 in forebrain excitatory neurons rescues the L66H model, and introducing a degradation-resistant RNF220 variant rescues the R213W model.

Two classes of ZC4H2 pathogenic mutations emerge: a loss-of-function class disrupting AMPA receptor subunit regulation (GluA1/GluA2) and a gain-of-function class suppressing inhibitory GABAA receptor subunits β1/β2 while preserving AMPA regulation.

Therapeutic implications are mutation-specific: muscimol, a GABAA agonist, restores inhibitory transmission and improves cognition in L66H/y mice but not in R213W/y mice, whereas an AMPAR antagonist like perampanel has the opposite effect, supporting mutation-stratified treatment approaches.

The work reframes ZC4H2-associated rare disorder (ZARD) as a disease spectrum where different mutations yield similar cognitive deficits through distinct synaptic mechanisms, implying mutation-specific interventions over diagnosis-first strategies.